Invion Limited (FRA:7C8)

Market Cap	2.55M -55.4%
Revenue (ttm)	233.32K
Net Income	-3.41M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0210
Previous Close	0.0210
Day's Range	0.0210 - 0.0210
52-Week Range	0.0200 - 0.0895
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Invion

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7C8

Financial Performance

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error